Search
forLearn
5 / 801 resultslearn Thymosin Beta 4
learn Beclomethasone
learn tamsulosin
learn Beta sitsterol
Research
5 / 366 resultsresearch Anti-acne drugs in phase 1 and 2 clinical trials
New anti-acne medications are being tested to offer alternatives to current treatments.
research Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils
The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.
research Liquid Chromatography-Mass Spectrometry-Based In Vitro Metabolic Profiling Reveals Altered Enzyme Expressions in Eicosanoid Metabolism
The method reliably profiles eicosanoids and shows epitestosterone reduces their levels, similar to common anti-inflammatory drugs.
research The Role of Cytochrome P-450 in Dermatology
Cytochrome P-450 enzymes in the skin help break down various substances and could be targeted to treat skin conditions.
research Altered Hormone and Bioactive Lipid Plasma Profile in Rodent Models of Polycystic Ovarian Syndrome Revealed by Targeted Mass Spectrometry
Rodent models of PCOS show some hormone changes similar to humans, but also have key differences.
Community Join
5 / 1000+ resultscommunity EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Using WinLevi (Clascoterone) for Seborrheic Dermatitis and Acne
Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.
community A better treatment would be a localized 5ar inhibitor that breaks down when it enters blood or leaves hair follicle
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
community Pyrludimide (KX-826) or Breezula (clascoterone)
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.